Over the last few years, immunotherapy has cemented its dominant status in the management of cancer.
TIM3 Inhibitors Drug Clinical Trials & Market Opportunity Insight 2028 Report Highlights:
- Insight on Emerging TIM3 Inhibitors in Development As Monotherapy & combination Therapy
- Future Market Opportunity Insight From First Drug Approval: 2024 - 2028
- Insight On TIM3 Inhibitors Drug In clinical Trials: > 15 Drugs
- TIM3 Inhibitors Drug In Clinical Trials Insight By Country, Company, Indication
- Comprehensive Clinical Insight On Biomarker Identified During Clinical Trials
- TIM3 Targeted Therapy Application By Various Cancers
Download Report:
Over the last few years, immunotherapy has cemented its dominant status in the management of cancer. Among all immunotherapeutic approaches, therapeutic antibodies have gained maximum interest in the global market owing to their ability to specifically target the receptors present on the cancer cell. The advancement in the field of biotechnology has enhanced the knowledge about cancer biology and has identified several receptors which are generally expressed on cancer cells, and therefore have the potential to become target for the therapeutic antibodies.
Research studies have recently identified T-cell immunoglobulin and mucin domain-3 (TIM-3) which is an immune checkpoint receptor. Under normal physiological conditions, TIM-3 is present in ifferent types of immune cells, including T cells, regulatory T cells (Tregs), dendritic cells (DCs), B cells, macrophages, nature killer (NK) cells, and mast cells. Apart from this, TIM-3 has been shown to promote immune tolerance, and overexpression of TIM-3 is associated with more advanced stage and poor prognosis of disease. The overexpression of TIM-3 is found to be associated with wide range of cancer cells including acute myeloid leukemia, melanoma, non-small cell lung cancer, head and neck cancer, and several others.
Owing to these characteristics, researchers suggested the promising therapeutic potential of TIM-3 inhibition as an approach to target the cancer cells. Since then, pharmaceutical companies have invested large amounts in the development of novel TIM-3 targeting antibodies which are currently present in clinical development. The pipeline of novel TIM-3 targeted drugs is highly concentrated with majority of candidates including MBG453, TSR-22, Sym023, LY3321367, BGB-A425, BMS-986258, and other which are mainly present in phase-II/III clinical development. MBG453 is one of the most advanced stage product which is currently ongoing phase-III clinical trials and is therefore expected to gain market authorization by 2024.
Although monotherapy with TIM-3 inhibitors have shown encouraging response, clinical trials are exploring the role of these drugs in combination therapy. The amalgamation of two or more drugs with synergistic mechanism of action ensures high specificity and efficacy towards the treatment of diseases as well as also overcome the issue of drug resistance. The novel TIM-3 inhibitors have shown encouraging response in combination with PD-1/PD-L1 inhibitors or other cancer targeted regimens in clinical trials. For instance, Cobolimab in combination with dostarlimab (Jemperli) in patients with advanced melanoma has shown that novel combination was safe and led to objective response rate (ORR) and immune-related ORR of 42.9% consisting of all partial responses in patients with advanced or metastatic melanoma.
The promising response of TIM-3 in combination therapy and the progress in cancer immunotherapeutic approaches has also led to the designing of TIM-3 targeting bispecific antibodies. Bispecific antibodies are novel constructs which have the ability to bind to two different antigens simultaneously. Currently, only a few bispecific antibodies have entered the clinical pipeline, including AZD7789 developed by AstraZeneca, and RO7121661 developed by Roche. However, it is suggested that coming years will witness rapid introduction of bispecific antibodies which is mainly attributed to its advantages over monotherapy or combination therapy in terms of cost, efficacy, and safety.
Several parameters including rise in research and development activities, surge in number of clinical trials, and encouraging response of TIM-3 therapy in the management of cancer are the major factors which are driving the growth of market. Other factors such as increase in prevalence of cancer, unmet need of targeted therapy, and huge adoption rates of immunotherapy will also have a positive impact on the growth of market. The major companies in global TIM-3 targeted therapy market are Novartis, Bristol Myers Squibb, BeiGene, Eli Lilly, Curis, and others.
Contact:
Neeraj Chawla
Kuick Research
Research Head
+91-9810410366